A detailed history of Tower Research Capital LLC (Trc) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 8,298 shares of NUVB stock, worth $19,168. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,298
Previous 19,873 58.24%
Holding current value
$19,168
Previous $58,000 67.24%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.3 - $3.83 $26,622 - $44,332
-11,575 Reduced 58.24%
8,298 $19,000
Q2 2024

Aug 13, 2024

BUY
$2.58 - $3.69 $8,150 - $11,656
3,159 Added 18.9%
19,873 $58,000
Q1 2024

May 15, 2024

BUY
$1.46 - $3.97 $11,882 - $32,311
8,139 Added 94.92%
16,714 $60,000
Q4 2023

Feb 13, 2024

SELL
$0.96 - $1.53 $3,495 - $5,570
-3,641 Reduced 29.81%
8,575 $12,000
Q3 2023

Nov 14, 2023

BUY
$1.26 - $2.1 $11,158 - $18,597
8,856 Added 263.57%
12,216 $16,000
Q2 2023

Aug 14, 2023

SELL
$1.56 - $1.84 $48,219 - $56,874
-30,910 Reduced 90.2%
3,360 $6,000
Q1 2023

May 09, 2023

BUY
$1.6 - $2.48 $38,904 - $60,301
24,315 Added 244.25%
34,270 $57,000
Q4 2022

Feb 10, 2023

BUY
$1.68 - $2.5 $2,014 - $2,997
1,199 Added 13.69%
9,955 $19,000
Q3 2022

Nov 10, 2022

SELL
$0.29 - $4.04 $187 - $2,609
-646 Reduced 6.87%
8,756 $20,000
Q2 2022

Aug 15, 2022

BUY
$3.24 - $5.85 $26,451 - $47,759
8,164 Added 659.45%
9,402 $30,000
Q1 2022

May 12, 2022

SELL
$4.6 - $8.83 $6,209 - $11,920
-1,350 Reduced 52.16%
1,238 $7,000
Q4 2021

Feb 14, 2022

SELL
$7.75 - $10.05 $8,602 - $11,155
-1,110 Reduced 30.02%
2,588 $22,000
Q3 2021

Nov 15, 2021

BUY
$7.78 - $10.0 $22,663 - $29,130
2,913 Added 371.08%
3,698 $37,000
Q2 2021

Aug 16, 2021

BUY
$9.22 - $14.48 $1,014 - $1,592
110 Added 16.3%
785 $7,000
Q1 2021

May 17, 2021

BUY
$9.0 - $14.57 $6,075 - $9,834
675 New
675 $7,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $502M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.